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Background:  Coronavirus  disease  2019  (COVID-19)  is caused  by severe  acute  respiratory  syndrome  coro-
navirus 2  (SARS-CoV-2),  within  few months  of  being  declared  as  a  global  pandemic  by WHO,  the number
of confirmed  cases  has  been  over 75  million  and over  1.6  million  deaths  since  the  start  of  the  Pandemic
and  still  counting,  there  is no  consensus  on  factors  that  predict  COVID-19  case  progression  despite  the
diversity  of  studies  that reported  sporadic  laboratory  predictive  values  predicting  severe  progression.
We  review  different  biomarkers  to systematically  analyzed  these  values  to evaluate  whether  are  they
are  correlated  with  the  severity  of  COVID-19  disease  and  so  their  ability  to  be a predictor  for  progression.
Methods:  The  current  meta-analysis  was  carried  out  to identify  relevant  articles  using  eight  different
databases  regarding  the  values  of  biomarkers  and risk  factors  of  significance  that  predict  progression
of  mild  or  moderate  cases  into  severe  and  critical  cases.  We  defined  the  eligibility  criteria  using  a PICO
model.
Results:  Twenty-two  relevant  articles  were  selected  for  meta-analysis  the  following  biomarkers  C-reactive
protein,  interleukin-6,  LDH, neutrophil,  %PD-1  expression,  D-dimer,  creatinine,  AST  and  Cortisol  all
recorded  high  cut-off  values  linked  to severe  and  critical  cases  while  low  lymphocyte  count,  and  low
Albumin  level  were  recorded.  Also,  we  meta-  analyzed  age and  comorbidities  as  a  risk  factors  of  progres-
sion  as  hypertension,  Diabetes  and  chronic  obstructive  lung  diseases  which  significantly  correlated  with
cases  progression  (p  <  0.05).
Conclusions:   The  current  meta-analysis  is  the  first  step  for analysing  and getting  cut-off  references  values
of  significance  for  prediction  COVID-19  case  progression.  More  studies  are  needed  on  patients  infected
with  SARS-CoV-2  and  on  a larger  scale  to establish  clearer  threshold  values  that  predict  progression  from
mild  to severe  cases.  In addition,  more  biomarkers  testing  also  help  in building  a scoring  system  for  the
prediction  and guiding  for proper  timely  treatment.
©  2021  The  Authors.  Published  by  Elsevier  Ltd on  behalf  of King  Saud  Bin  Abdulaziz  University  for
Health  Sciences.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Coronaviruses (CoV) are a group of viruses that lead to diseases
variable from mild to many serious diseases such as Middle Eastern
respiratory syndrome (MERS-CoV) and severe acute respiratory
syndrome (SARS-CoV). Dec. 31, 2019, the Chinese Health Authority
notified the World Health Organization (WHO) of numerous cases
of pneumonia of unknown etiology in the city of Wuhan, in the
area of Hubei, in central China [1]. On January 7, a new coronavirus,
originally abbreviated as 2019-nCoV by WHO, was  identified by
a patient’s throat swab sample, has not been recognized before in
humans [2,3]. Subsequently, this pathogen was renamed as coro-
navirus 2 severe acute respiratory syndrome (SARS-CoV-2) and the
coronavirus designated by WHO  2019 (COVID-19) [4] by January
30, in China 7736 cases recorded, 12,167 suspected and 82 cases
had been perceived in 18 countries. Accordingly, WHO  stated the
SARS-CoV-2 epidemic as an international public health emergency
[5]. On 11 March 2020, the World Health Organization (WHO)
stated that COVID-19 as a pandemic [6]. While writing this review,
worldwide cases over 75 million and over 1.6 million deaths
which are increasing with the upward curve [7]. The dependence
on CT scan findings to detect and diagnose cases of coronavirus
affection although accurate, does not estimate or predict which
patient will go for a severe or lethal course [8,9]. Therefore, it
is mandatory to identify mild/moderate patients who can pass
to severe/critical condition and give them efficient treatment to
prevent deterioration as the early proper treatment of cases prone
to severe/critical malignant progression are important ways to
reduce mortality [10]. Unfortunately, most investigators focused





562aboratory, and CT imaging results [11–14]. Some have focused on
nding risks for death [15,16]. Few have presented their data and
entioned the prediction of progression of mild COVID-19 cases,
ut still, the work is separate and there is no review to gather
nd filter the information of significance. So our purpose is to fill
he gap by doing meta-analysis of published researches based
n criteria to obtain reference figures of statistically significant
iomarkers levels (p < 0.05) and getting mean number of all means
f the analyzed papers to be easily consulted to detect cases that
xpected to deteriorate into severe/critical condition as a first
tep to start building a scoring system that can be objectively
xpect COVID-19 case progression which is best known to our
nowledge this is the first time to be done. This will help doctors to
egin efficient aggressive treatment without delay by adequately
redicting severe/critical cases which will improve survival rates
nd reduce both illness and fatality in the COVID-19 pandemic.
ethods
Using an online database, to conduct a meta-analysis on the
arly prediction of COVID-19 cases prone to deterioration. The main
rticles are mainly taken from PubMed, Google Scholar, MEDLINE,
pToDate, Medscape, Embase, Web  of Science, and the preprint
erver medRxiv using the terms “COVID-19”, “SARS-CoV-2”, “pre-
iction of severe/critical cases”, “Vulnerability Index”, “Risk factors
ortality”, “prediction of survival”, “prediction of malignant pro-ression”, “risk score” are the keywords for our search. Publications
ere left out if they had inappropriate data and were not appro-
riate to the specific purpose of our review. All relevant study
eference lists have been selected to identify missing publica-
































Fig. 1. Systematic review flow chart for literature refinement.
tions. After duplicates & irrelevant were removed, we  identified
2000 papers. Search, of titles and abstracts were conducted by
6 independent working researchers by applying eligibility crite-
ria and filter the relevant ones. Disagreements were resolved by
discussion. We  defined the eligibility criteria using a PICO model
as follows. Population: no specific reference population. Inter-
vention: Noninvasive lab investigations and biomarkers assay.
Comparison: Imaging investigations, clinical symptoms progres-
sion or intra-individual pre-post comparison. Outcome: Patients
with certain biomarkers levels progressed from mild/moderate to
severe/critical. All eligible deemed articles have been retrieved for
full-text review [Fig. 1]. We  included studies for meta-analysis






Characteristics of the included studies in meta-analysis.
Author Study design Country Cohort size Biomarkers
studied/como
Wang et al. [11] Retrospective cohort,
single center
China 138 Neutrophil cn
cnt, LDH
Yang et al. [12] Retrospective cohort,
multi center
China 149 Neutrophil cn
cnt, D-dimer, 
creatinine, LD
Zhou et al. [15] Retrospective cohort,
multi center




Diao  et al. [24] Retrospective cohort,
multi center
China 522 Lymphocyte c
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ith severe or mild illness, also those had death groups and sur-
ivors. We  considered severity of the disease as “mild” for those
atients described in the studies as mild or moderate cases, while
onsidered ‘severe’ for described as having severe disease, ICU cases
r required mechanical ventilation. Only studies of ≥30 patients
ere included. Only studies of score greater than 6 were consid-
red of high quality of total score 9 according to Newcastle-Ottawa
cale (NOS) guidelines that was  used by 4 independent reviewers,
isagreement was resolved by additional reviewer [17].
tatistical analysis
Meta-analyses were done using the metacount and metabin
unctions for continuous and binary variables respectively from
he R package meta in R Studio [18]. For each study with more
han one values of the biomarkers, a single value was  calculated
sing the method described in Higgins and Green [19]. An over-
ll weighted mean (SD) of the biomarkers was  estimated within
he mild and severe groups using standard weighted approach
ith built-in R functions. The overall difference in means or events
etween severe and mild patients were quantified by pooling the
ifferences provided by the original studies using Random effect
odels, and the results represented as forest plots. Results for age
nd biomarkers were given as Mean Difference, MD  (95%CI) while
hose of comorbidities as Relative Risks, RR (95%CI). Statistical het-
rogeneity between studies was assessed using I2. For results with
ore than 2 studies, publication bias was  assessed using the Egger
egression [20].
esults
iterature screening and assessment
A total of 2400 records were identified from the databases. After
 detailed assessment, 22 studies involving 4138 COVID-19 patients
ere included in the meta-analysis (Fig. 1).
haracteristics of included studies
19 studies included in the meta-analysis were conducted in
hina examined Chinese patients, the remaining three were con-
ucted in Iran, Italy and Cameron. All included studies were
ublished in 2020. A large proportion of these studies (n = 20) were
ingle center data collected. All included studies received quality
cores of 6–9, indicating high quality (Table 1).
rbidity
Comments
t, Lymphocyte Higher Neutrophil count, LDH and lower lymphocyte





CT scan cannot exclude the diagnosis of COVID-19 as some
patients with COVID-19 can present with normal chest





Considered D-dimer > 1 g/mL could help clinicians to
identify patients with poor prognosis at an early stage.
nt, IL-6 Recorded significant reduction in T cell counts in
COVID-19 patients, and the surviving T cells appear
functionally exhausted. Also, they negatively corrected T
cells to IL-6. Considered Non-ICU patients with total T cells
counts < 800/L still require urgent intervention, even in
the immediate absence of more severe symptoms due to a
high risk for further deterioration in condition.
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Table  1 (Continued)
Author Study design Country Cohort size Biomarkers
studied/comorbidity
Comments
Liu et al. [34] Retrospective cohort,
single center
China 40 Neutrophil cnt, Lymphocyte
cnt, AST, LDH, creatinine,
D-dimer, CRP, hypertension,
Diabetes
Associated higher degree of lymphopenia and a
proinflammatory cytokines with COVID-19 disease
severity.
Feng  et al. [36] Retrospective cohort,
single center
China 132 Lymphocyte cnt, Neutrophil
cnt, CRP, IL-6, hypertension,
Diabetes, chronic obstructive
lung disease
Proposed CT scan as early screening could not satisfy every
patient in COVID-19 outbreak and considered use of
machine-learning algorithms to analyze clinical
symptoms, biomarkers and other clinical information as a
good tool for diagnosis and early prediction of cases
prognosis before further CT examination
Qin  et al. [37] Retrospective cohort,
single center
China 452 CRP, IL-6, Neutrophil cnt,
Lymphocyte cnt
Compared different inflammatory biomarkers higher
levels in severe and non-severe COVID-19 cases
Liu  et al. [39] Retrospective cohort,
single center
China 140 IL-6, lymphocytes, neutrophils,
AST, CRP, Creatinine, D-Dimer
They measured different biomarkers and correlated them
with disease progression
Wu  et al. [41] Retrospective cohort,
single center
China 201 IL-6 Significantly correlated higher IL-6 levels in severe cases
Chen  et al. [43] Retrospective cohort,
single center
China 99 IL-6 Considered high IL-6 levels one of the measures that may
detect COVID-19 severity.
Ji  et al. [51] Retrospective cohort,
single center
China 33 CRP Statistically significant increase in CRP with increase
severity of the disease and considered it one of the
measures can be used to judge severity
Etoga et al. [53] Cross sectional single
center
Cameroon 80 Cortisol This study recorded higher levels of cortisol among
COVID-19 cases who need further oxygen therapy than
those of mild condition
Ramezani et al. [54] Cross sectional single
center
Iran 30 Cortisol This study significantly correlated higher levels of cortisol
in  non-survived patients of Covid-19 in comparison with
surviving patients.
Li  et al. [55] Retrospective cohort,
single center
China 132 CRP This study recorded noticeable difference of CRP between
mild and severe critical cases
Tang  et al. [56] Retrospective cohort,
single center
China 183 D-Dimer Recorded higher levels of D-Dimer among non survivors
COVID-19 cases
Zhang et al. [57] Retrospective cohort,
single center
China 343 D-Dimer They study considered D-dimer level on admission > 2.0
g/mL could eff ;ectively predict hospital mortality in
patients with COVID-19
Huang  et al. [58] Prospective cohort,
single center
China 41 IL-6, D-Dimer Recorded higher levels of IL-6 and D-dimer among severe
cases
Cheng  et al. [60] Prospective cohort,
single center
China 701 Creatinine They correlated high level of creatinine with severity and
worse outcome in COVID-19 cases
Luo  et al. [61] Retrospective cohort,
single center
China 35 LDH Considered higher levels of LDH may indicate severity of
the disease by their recorded levels of LDH in severe cases
Li  et al. [62] Retrospective cohort,
single center
China 134 Lymphocyte cnt, Neutrophils
cnt, D-dimer, albumin, AST,
creatinine, IL-6, CRP,
hypertension
Reached cut off value for decrease in albumin levels with
the progression of the disease even they considered it as
an  independent predictor (cut-off point: 35.1 g/L) of the
risk of non survivors among critical COVID-19 cases
Ferrari  et al. [63] Retrospective cohort,
single center
Italy 207 LDH LDH higher level among COVID-19 cases and considered it
may  help in diagnosis of such cases
Mo  et al. [64] Retrospective cohort,
single center
China 155 LDH 
Table 2
Egger’s test of funnel plot asymmetry (publication bias).
Variable Bias Statistics P value
Age −1.5 −1.3 0.28
Lymphocytes −0.3 −0.1 0.92
D-Dimer 3.1 3.1 0.05
IL-6 4.7 0.9 0.42
Neutrophils count 0.03 0.01 0.99
Creatinine 0.2 0.1 0.92
CRP  0.3 0.1 0.94
LDH 6 1.3 0.33
Hypertension 1.4 1.0 0.50










Severe cases recorded significantly higher level of AST vs mildBias: the intercept from the Egger’s regression; p value of <0.05 signifies that the
intercept is different from 0 and implying significant publication bias.
Publication biasThe calculated p values of Egger’s and the Begg’s test for all ana-
lyzed studies outcomes showed no publication bias (Table 2). The




564Recorded higher levels among complicated cases and
correlated LDH biomarker with the development of the
disease.
ge distribution
Severe cases were on average 16 years significantly older than
hose with Mild cases: Age difference 16.4 years (95%CI; 11.4, 21.3).
here are no major differences in the study estimates and publica-
ion bias (I2 is <75%, Bias = −1.4, p value = 0.28). The mean age of
evere group cases was  66.9 (STD 15.4) (Fig. 2A).
lbumin
Albumin level was  significantly lower in severe cases vs mild
ases. The difference was  of −4.7 g/L (95% CI; −5.8, −3.7). The mean
lbumin level in severe group cases was 30.4 g/L (STD 6.1) (Fig. 2B).
spartate aminotransferaseases with difference of 18.6 IU/L (95% CI; 7.8–29.5), with no major
ifference in in the study estimates (I2 is <75%). The recorded mean
ST level in severe group cases was  42.4 IU/L (STD 19.5) (Fig. 2C).









Fig. 2. (A–F): Meta-analysis of the difference between COVID-19 patients with seve
Creatinine (E) C-reactive protein (F) D-Ddimer. (G–L): Meta-analysis of the differen
(I)  Lymphocytes (J) Neutrophil count (K) %PD-1 expression on T cells (L) Cortisol.
Creatinine
Creatinine level showed significantly higher levels in severe vs
mild cases with difference of 12.00 mol/L (95% CI; 6.2; 17.8),
with no major difference in the study estimates (I2 is <75%).
Mean creatinine level in severe cases was 77.1 mol/L (STD 31.2)
(Fig. 2D).
C-reactive protein
C-reactive protein level was higher in severe vs mild cases with
difference of 19.6 mg/L (95% CI; 0.8; 38.4), however there was  a
major difference in the study estimates (I2 is >75%) with no sig-
nificant publication bias (Bias = 0.3, p value = 0.9) Mean C-reactive





565ild disease in: (A) Mean age (B) Albumin level (C) Aspartate aminotransferase (D)
ween COVID-19 patients with severe vs mild disease in: (G)  Interleukin-6 (H) LDH
-dimer
D-Dimer recorded higher levels in severe vs mild cases with
ean difference of 5.8 g/mL (95% CI; 0.7; 10.9), however was  a
ajor difference in the study estimates (I2 is >75%). Publication
ias was  insignificant publication (Bias= -3.4, p value = 0.5). Mean
-Dimer level in severe cases was 12.9 g/mL (STD 52.7) (Fig. 2F).
nterleukin-6
IL-6 showed higher levels in severe vs mild cases with mean
ifference of 10.3 pg/mL (95% CI; 1.6; 19.0), there was a major differ-
nce in the study estimates (I2 is >75%). No significant publication
ias (Bias = 4.7, p value = 0.4). Mean IL-6 level in severe cases was
9.6 pg/mL (STD 138) (Fig. 2G).


































Fig. 3. (A–C): Meta-analysis of the difference between COVID-19 patients with seve
LDH
LDH level was higher in severe vs mild cases with mean dif-
ference of 143.52 U/L (95% CI; 50; 237.1), major difference was
recorded in study estimates (I2 is >75%). No significant publica-
tion bias (Bias = 6, p value = 0.3). Mean LDH level in severe cases
was 382 U/L (STD 221) (Fig. 2H).
T-Lymphocytes count
T-Lymphocytes count was lower in severe vs mild cases, the
mean difference was -0.24 × 109/L (95% CI; −0.45; −0.03), the
study estimate recorded major difference estimates (I2 is >75%). No
significant publication bias (Bias = −0.3, p value = 0.9). Mean lym-
phocyte count in severe cases was 0.8 × 109/L (STD 0.46) (Fig. 2I).
Neutrophil count
Neutrophil count recorded higher levels in severe vs mild cases,
the mean difference was  2.3 × 109/L (95% CI; 0.9; 3.8), the study
estimate recorded major difference estimates (I2 is >75%). No sig-
nificant publication bias (Bias = 0.03, p value = 0.9). Mean neutrophil
count in severe cases was  6.1 × 109/L (STD 5.8) (Fig. 2J).
%PD-1 expression on T cells
%PD-1 expression on T-Lymphocytes was higher in severe vs
mild cases, with mean difference of 10.8 (95% CI; 3.7; 17.8), there
was no significant heterogeneity in the studies used (I2 is <75%).
Mean of %PD-1 expression on T lymphocytes (the marker of T-cell
exhaustion) in severe cases was 47 (STD 24) (Fig. 2K).
Cortisol
Although there are only two published studies about cortisol
level among COVID-19 cases we included in our meta-analysis
to check the significance of this biomarker and accordingly to
recommend its importance for further studies. Cortisol recorded
significant higher level in severe vs mild cases with mean difference
of 213.3 nmol/L (95% CI; 142.4; 284.2), No significant heterogeneity
was recorded in study estimates (I2 is >75%). Mean cortisol level in
severe cases was 794 nmol/L (STD 264) (Fig. 2L).
Hypertension
Co-morbidity with hypertension was twice much more com-
mon in severe cases vs mild cases with RR 2.1(95% CI; 1.5; 3.0), No
significant heterogeneity recorded in study estimates (I2 is < 75%)
or publication bias (Bias = 1.4, p value = 0.5) (Fig. 3A).Diabetes
Co-morbidity with diabetes was twice and half much more com-




566ild disease in: (A) Hypertension (B) Diabetes (C) Chronic obstructive lung disease.
ignificant heterogeneity recorded in study estimates (I2 is <75%)
r publication bias (Bias = 0.06, p value = 0.9) (Fig. 3B).
hronic obstructive lung disease
Co-morbidity with chronic obstructive pulmonary disease was
bout four times much more common in severe cases vs mild
ases with RR 3.9 (95% CI; 0.9; 16.1), No significant heterogeneity
ecorded in study estimates (I2 is <75%) (Fig. 3C).
tudy limitation
Our meta-analysis included a large number of COVID-19
atients, but there are some limitations due to heterogeneity found
n some studies, as well as most of the studies were from China and




COVID-19 is a respiratory infection with common signs includ-
ng respiratory symptoms, fever, cough, and difficulty in breathing.
n severe cases, the infection can cause pneumonia, severe acute
espiratory syndrome, renal failure, and death [21,22]. Based on the
taging of the infectious disease: The prodromal period is a phase in
hich the host begins to manifest general signs and symptoms. The
penly symptomatic period is a phase in which the disease signs or
ymptoms are more evident, with positive laboratory results and
hest imaging. For ICU patients, the ICU period is a phase in which
he symptoms are more evident and severe. The period of decline
s a phase in which clinical symptoms begin to decrease, labora-
ory results and chest imaging improve, and saturation of oxygen
eturns to normal [23,24]. The Chinese National Health Commission
lassified clinical types into mild/moderate/severe/critical [25].
actors that favor disease severity and worsen the prognosis
Factors that favor disease severity and complications: Select-
ng cases with risk factors that could progress through a serious
nd complicated COVID-19 disease course is like selecting between
eath and life. Several researchers have investigated many risk fac-
ors, some findings were statistically significant (p < 0.05).
ge and comorbiditySevere cases are those prone to serious complications and
re at risk of death. The danger of serious complications from
OVID-19 is greater for some vulnerable populations, particularly
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[10,21,26–30]. Some studies reported advanced age and comor-
bidity with hypertension, as the most important risk factors for
malignant progression [31]. The hazard of death was difficult to cal-
culate, but some studies on COVID-19 patients in Wuhan reported
that the risk of death rises with age and for those with diabetes,
heart disease, clotting disorders. Since the fatality rate has changed
from an average of 1%, to be 6% for persons with cancer, hyperten-
sion or chronic respiratory diseases, 7% for diabetes, and 10% for
heart diseases. There was also a strong age gradient; the fatality
rate for those over 80 was > 15% [15].
Our meta-analysis confirmed older age at more risk for case pro-
gression as we recorded age was higher by 16 years in COVID-19
severe cases than mild, with overall mean age of analyzed severe
cases 66.9 (STD 15.4). Also, we recorded comorbidity of hyperten-
sion increase risk of progression from mild to severe twice, Diabetes
twice and half, and Chronic obstructive lung disease showed four
times which is the highest risk of progression among our analyzed
studies.
Biomarkers of prediction for case progression
Inflammatory markers
Lymphopenia is a common feature in COVID-19 patients and
could be a critical factor associated with disease severity and
mortality [24,32,33,35–37]. Even some studies considered low lym-
phocyte count is a biomarker is of >90% accuracy or of vital role for
prediction of case progression that may  aid as a possible therapeutic
target [27]. Diao et al. studied lymphocytes function by measuring
exhaustion markers and recorded increased expression of PD-1 and
Tim-3 in T cells in cases proceeded from prodromal to symptomatic
phases, further indicating T-cell depletion. The authors stated that
these counts even in patients without intensive care may  require
aggressive intervention even in the absence of serious symptoms
as liable to worsening of their condition [24]. Our meta-analysis on
%PD-1 expression on T-Lymphocytes as one of exhaustion markers
confirmed being higher in severe vs mild cases. The mean of %PD-1
expression in severe cases in studies analyzed was 47 (STD 24).
Many studies found a close and significant correlation between
IL-6 high levels and case progression and even mortality. Some are
negatively correlated it with low T-lymphocyte count and higher
expression of PD-1 among severe cases [16,24,27,38,39]. Our meta-
analysis confirmed higher levels of IL-6 in severe vs mild cases
with overall mean level in severe cases 29.6 pg/mL (STD 138). Sev-
eral studies recorded neutrophil count as an important biomarker
that can predict progression of mild cases into severe/critical one






The collected biomarkers of all meta-analyzed studies of statistical significance with calcu
for  prediction of progression from a mild/moderate case of COVID-19 into severe/critical 
Positive COVID-19 patient
Biomarkers of prediction progression of cases from mild/moderate to severe/critical
Non-high-risk groupa
A-Indicators of COVID-19 progression into severe/critical condition B
C-reactive protein ≥58.2 mg/L (STD 47) L
A
Neutrophil count ≥ 6.1 × 109/L (STD 5.8).
AT-Lymphocytes count ≤ 0.8 × 109/L (STD 0.46).
D-Dimer ≥12.9 g/mL (STD 52.7)
T  Cell Function: % PD-1 expression on T cells C
%  PD-1 On T-Cell ≥47 (STD 24)
Cytokines:
IL-6 ≥29.6 pg/mL (STD 138)
Cortisol level: ≥794 nmol/L (STD 264)
a Patient younger than 66.9 years (STD 15.4) with no comorbidity if show any indicator 
necessitates aggressive treatment even if CT findings not clear yet and the patient conditi
567Journal of Infection and Public Health 14 (2021) 561–569
t useful in surveillance and may  predict critically ill patients early
11,16,37,40,41]. Our results revealed higher neutrophil count in
evere vs mild cases, with the overall mean neutrophil count in
nalyzed studies is 6.1 × 109/L (STD 5.8). C-reactive protein was
ike a marker of common use several studies recorded higher levels
n severe/critical than mild COVID-19 cases and some considered it
o be of help for detection of case progression [10,27,35,39,41–51].
ur analysis confirmed higher levels of CRP among severe vs mild
OVID-19 cases with overall mean level in severe cases 58.2 mg/L
STD 47).
ortisol level
Three published studies on cortisol level in COVID-19 cases
ecorded higher level of cortisol among severe vs mild COVID-
9 cases [52–54]. Our meta-analysis confirmed its higher levels in
evere vs mild cases with over all mean of the studied severe cases
s 794 nmol/L (STD 264).
bnormal coagulation
Several studies recorded high levels of D-Dimer which reflect
bnormal coagulation results among severe vs mild COVID-19
ases. Some considered certain level could effectively predict in-
ospital mortality in patients although the recorded levels were
ifferent [11,15,27,39,55–57].
Our analysis confirmed D-Dimer higher levels in severe vs mild
ases with overall mean level in severe cases is 12.9 g/mL (STD
2.7).
ultiorgan injury
COVID-19 severe cases not only related to respiratory tract
nfection but also progression into severe complicated cases
nd increased mortality could be due to multiorgan injury.
ome studied worked on biomarkers those could reflect organs
njury as AST, creatinine, LDH and Albumin on which they
eported higher levels of the first three biomarkers and lower
evels of the fourth one among severe/critical cases. Some
trongly corrected decrease Albumin level with disease progres-
ion [11,16,27,39,41,46–49,58–64]. Our analysis confirmed higher
evels of AST, creatinine and LDH among severe vs mild covid-19
ases with overall mean levels in severe cases 42.4 IU/L (STD 19.5),
7.1 mol/L (STD 31.2), and 382 U/L (STD 221) respectively. Albu-
in  level was  significantly lower among severe cases with overall
ean level in severe cases is 30.4 g/L (STD 6.1).
lated mean of all recorded means in the studies of analysis to be a help key levels
case.
-Indicators of multiorgan injury
DH ≥382 U/L (STD 221)
spartate aminotransferase (AST), U/L ≥42.4 IU/L (STD 19.5)
lbumin ≤30.4 g/L (STD 6.1)
reatinine ≥77.1 mol/L (STD 31.2)
in this group considered a risk for progression into severe/ critical condition which
on still apparently mild.
M.M.  Khodeir et al. 
Table  4
The collected risk factors of meta-analyzed studies of statistical significance to help
as  a key for prediction of progression from a mild/moderate case of COVID-19 into
severe/critical case.
Positive COVID-19 patient




A-Age ≥ 66.9 (STD 15.4)
B-Any age with Comorbidity: Risk degree for progression


















3-Diabetes Twice and half
Reference keys and prediction of severity
We  collected the overall mean levels of our biomarkers of study
those all included studies in our meta-analysis to seal the gap, best
known to our knowledge not done before in any published meta-
analysis on COVID-19, and reach a possible prediction references
keys with their levels that can be used as a reference that can predict
sunsets for mild or moderate COVID-19 cases who are vulnerable
to progress into a severe course, entailing aggressive interventions
in absence of severe symptoms which will be of great value to
reduce the burden on intensive care and reduce complications and
mortality (Tables 3 and 4). We  considered it as the first step to
start building a scoring system that can be used for the prediction
that guides for proper timely treatment which will be of help to
reduce mortality. We  are working on another review article that
will explain the immunopathogenesis of COVID-19 and explain-
ing why these predictors are keys in predicting progression of the
cases to severe/critical, we also propose the possible solutions for
effective treatment.
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